Digene's DNA test for gonorrhea cleared in US:
This article was originally published in Clinica
The US FDA has cleared Digene's test for Neisseria gonorrhea DNA in cervical specimens from women with or without symptoms of the infection. The test is a signal amplified nucleic acid hybridisation assay that uses the same gene analysis technology employed in Digene's other women's cancer and infectious disease diagnostics. A common collection device will allow tests for human papilloma virus (HPV), chlamydia and gonorrhea to be performed on a single specimen, said Beltsville, Maryland-based Digene. The Hybrid Capture II gonorrhea test will be distributed by Abbott Laboratories, which also distributes the test in Europe, Africa and the Middle East.
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.